Market Research Logo

Venous Leg Ulcers (Crural ulcer) - Pipeline Review, H2 2015

Venous Leg Ulcers (Crural ulcer) - Pipeline Review, H2 2015

Summary

Global Markets Direct’s, ‘Venous Leg Ulcers (Crural ulcer) - Pipeline Review, H2 2015’, provides an overview of the Venous Leg Ulcers (Crural ulcer)’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Venous Leg Ulcers (Crural ulcer), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Venous Leg Ulcers (Crural ulcer) and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Venous Leg Ulcers (Crural ulcer)
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Venous Leg Ulcers (Crural ulcer) and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Venous Leg Ulcers (Crural ulcer) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Venous Leg Ulcers (Crural ulcer) pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
Reasons to buy
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Venous Leg Ulcers (Crural ulcer)
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Venous Leg Ulcers (Crural ulcer) pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Introduction
Global Markets Direct Report Coverage
Venous Leg Ulcers (Crural ulcer) Overview
Therapeutics Development
Pipeline Products for Venous Leg Ulcers (Crural ulcer) - Overview
Pipeline Products for Venous Leg Ulcers (Crural ulcer) - Comparative Analysis
Venous Leg Ulcers (Crural ulcer) - Therapeutics under Development by Companies
Venous Leg Ulcers (Crural ulcer) - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Venous Leg Ulcers (Crural ulcer) - Products under Development by Companies
Venous Leg Ulcers (Crural ulcer) - Companies Involved in Therapeutics Development
Adocia
CardioVascular BioTherapeutics, Inc.
CoDa Therapeutics, Inc.
CytoTools AG
FirstString Research, Inc.
Intralytix, Inc.
MacroCure Ltd.
MediWound Ltd.
Pergamum AB
RegeneRx Biopharmaceuticals, Inc.
Smith & Nephew Plc
Stratatech Corporation
Venous Leg Ulcers (Crural ulcer) - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
Biochaperone PDGF-BB - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Cathelicidin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Cell Therapy to Activate VEGF for Venous Leg Ulcers and Diabetic Foot Ulcers - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CL-05 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CODA-001 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CureXcell - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CVBT-141B - Drug Profile
Product Description
Mechanism of Action
R&D Progress
EscharEx - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Granexin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
HP-802247 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
LL-37 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
RGN-137 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
WPP-201 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Venous Leg Ulcers (Crural ulcer) - Recent Pipeline Updates
Venous Leg Ulcers (Crural ulcer) - Dormant Projects
Venous Leg Ulcers (Crural ulcer) - Discontinued Products
Venous Leg Ulcers (Crural ulcer) - Product Development Milestones
Featured News & Press Releases
Jul 22, 2015: RegeneRx Receives Notice of Acceptance for Australian Patent for Key TB4 Peptide Fragment
Apr 21, 2015: SCRA Technology Ventures Company Shares Phase 2 Results
Apr 15, 2015: CytoTools: Recruitment Of Patients Now Complete For European Studies On Diabetic Foot And Ulcus Cruris Indications
Oct 13, 2014: Smith & Nephew announces top-line results of HP802-247 Phase 3 study
May 05, 2014: Subsidiary DermaTools Biotech starts European clinical phase II/III trial with wound healing medication DermaPro for ulcus cruris indication
Jan 09, 2013: CoDa Therapeutics Announces Positive Results From Phase IIb Study Of Nexagon In Chronic Venous Leg Ulcers
Sep 11, 2012: Healthpoint Biotherapeutics Initiates Phase III Study Of Investigational Cell-Based Therapy For Venous Leg Ulcers
Aug 02, 2012: Healthpoint Biotherapeutics Announces Publication Of Phase IIb Study Results Of Investigational Cell-Based Therapy In Lancet
Jul 25, 2012: Healthpoint Biotherapeutics Announces Phase II Trial Results Of HP802-247 For Venous Leg Ulcers
Aug 04, 2011: Healthpoint Biotherapeutics Announces Positive Results From Phase IIb Trial Of HP802-247 In Venous Leg Ulcers
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Venous Leg Ulcers (Crural ulcer), H2 2015
Number of Products under Development for Venous Leg Ulcers (Crural ulcer) - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Development, H2 2015
Products under Development by Companies, H2 2015
Venous Leg Ulcers (Crural ulcer) - Pipeline by Adocia, H2 2015
Venous Leg Ulcers (Crural ulcer) - Pipeline by CardioVascular BioTherapeutics, Inc., H2 2015
Venous Leg Ulcers (Crural ulcer) - Pipeline by CoDa Therapeutics, Inc., H2 2015
Venous Leg Ulcers (Crural ulcer) - Pipeline by CytoTools AG, H2 2015
Venous Leg Ulcers (Crural ulcer) - Pipeline by FirstString Research, Inc., H2 2015
Venous Leg Ulcers (Crural ulcer) - Pipeline by Intralytix, Inc., H2 2015
Venous Leg Ulcers (Crural ulcer) - Pipeline by MacroCure Ltd., H2 2015
Venous Leg Ulcers (Crural ulcer) - Pipeline by MediWound Ltd., H2 2015
Venous Leg Ulcers (Crural ulcer) - Pipeline by Pergamum AB, H2 2015
Venous Leg Ulcers (Crural ulcer) - Pipeline by RegeneRx Biopharmaceuticals, Inc., H2 2015
Venous Leg Ulcers (Crural ulcer) - Pipeline by Smith & Nephew Plc, H2 2015
Venous Leg Ulcers (Crural ulcer) - Pipeline by Stratatech Corporation, H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Stage and Target, H2 2015
Number of Products by Stage and Mechanism of Action, H2 2015
Number of Products by Stage and Route of Administration, H2 2015
Number of Products by Stage and Molecule Type, H2 2015
Venous Leg Ulcers (Crural ulcer) Therapeutics - Recent Pipeline Updates, H2 2015
Venous Leg Ulcers (Crural ulcer) - Dormant Projects, H2 2015
Venous Leg Ulcers (Crural ulcer) - Discontinued Products, H2 2015
List of Figures
Number of Products under Development for Venous Leg Ulcers (Crural ulcer), H2 2015
Number of Products under Development for Venous Leg Ulcers (Crural ulcer) - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Top 10 Targets, H2 2015
Number of Products by Stage and Top 10 Targets, H2 2015
Number of Products by Top 10 Mechanism of Actions, H2 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
Number of Products by Top 10 Routes of Administration, H2 2015
Number of Products by Stage and Top 10 Routes of Administration, H2 2015
Number of Products by Top 10 Molecule Types, H2 2015
Number of Products by Stage and Top 10 Molecule Types, H2 2015

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report